

CENTENNIAL, Colo., September 11, 2012 – Cell>Point announced today that Cardiovascular Imaging Technologies presented a Phase 1b clinical trial abstract for its cardiology imaging agent, ^{99m}Tc-EC-G (^{99m}Technetium-EthylenediCysteine-n-acetyl-Glocosamine), used to image ischemic patients during rest and exercise stress testing at the American Society of Nuclear Cardiology 2012 Meeting on September 6, 2012.

The abstract titled *“Myocardial Uptake of Novel Tc-99m Labeled Glucose Analog (Tc-99m EC-DG) in Normal and Ischemic Subjects during Rest and Exercise Stress Testing”* is available at this link [ASNC/EC-G](#). Abstract conclusion: ^{99m}Tc-EC-DG was found to be absorbed by abnormal myocardial tissue when stimulate by exercise stress. Furthermore, ^{99m}Tc-EC-DG may have the potential for detecting ischemia in the absence of exercise in a significant fraction of patients. Please note ^{99m}Tc-EC-DG is the same as ^{99m}Tc-EC-G.

About ^{99m}Tc-EC-G

^{99m}Tc-EC-G is Cell>Point’s cancer and cardiovascular diagnostic imaging agent. It is the first product stemming from Cell>Point’s EC Technology drug-development platform.

A SPECT camera is used to take a picture of cancer or cardiovascular disease after ^{99m}Tc-EC-G is administered. SPECT cameras are 25-fold more prevalent than, and one-quarter the cost of, PET cameras, which are presently the standard for cancer diagnosis and staging.

More information on ^{99m}Tc-EC-G and EC Technology can be found at the Cell>Point website (www.cellpointweb.com) under Technology/Pipeline.

About Cell>Point

Cell>Point is a late-stage biopharmaceutical company developing universal molecular imaging agents and molecular therapeutics for the diagnosis, treatment and monitoring of cancer, heart, and other diseases. Cell>Point has exclusive license to five drug-development platforms, all from The University of Texas M. D. Anderson Cancer Center in Houston, a world leader in cancer research and care. Information on Cell>Point’s drug candidates, recent press releases, and patents and patent filings can be obtained through its website at www.cellpointweb.com. The company is headquartered in Centennial, Colo., and has additional offices in San Francisco and Houston.